JAMA Cardiology publishes findings from Amgen's 4-year study of Repatha

The results from Amgen’s four-year follow up OSLER-1 study on Repatha, which is so far the longest PCSK9 inhibitor clinical trial, were recently published in JAMA Cardiology.
The results show that Repatha added to the standard of care led to a 57 percent reduction in median low-density lipoprotein cholesterol (LDL-C).
"For patients with cardiovascular disease, persistent LDL-C reduction is an important component of managing this chronic disease," Dr. Michael Koren with the Jacksonville Center for Clinical Research said. "These results reinforce that adding Repatha to the cardiovascular standard of care can achieve additional sustained LDL-C reductions over several years with no increased risk of safety concerns for patients who continue to struggle with elevated cholesterol levels."
The OSLER-1 open-label extension study involved 1,324 patients and monitored Repetha’s effectiveness in terms of the durability of its LDL-C reductions and the incidences of adverse events. The study found that patients who reached four years of follow up on the drug achieved median LDL-C of 60mg/dL, with no new safety concerns were identified and no neutralizing antibodies observed.
"Safely reducing LDL-C over the long term is an important treatment objective given that many patients with elevated cholesterol will experience one or more cardiovascular events in their lifetime," Dr. Sean Harper, Amgen's executive vice president of Research and Development, said. "These long-term follow-up data reaffirm our conviction that Repatha is a valuable tool in the management of cardiovascular disease."